Which has better earnings & valuation, CBIO or INVA?

Innoviva has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Crescent Biopharma $10.84M 46.63 -$153.94M -$10.91 N/A Innoviva $411.33M 4.03 $271.17M $6.01 3.73

Does the media favor CBIO or INVA?

In the previous week, Crescent Biopharma and Crescent Biopharma both had 4 articles in the media. Innoviva's average media sentiment score of 0.47 beat Crescent Biopharma's score of 0.33 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Innoviva 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, NVAX or CBIO?

Novavax has higher revenue and earnings than Crescent Biopharma. Novavax is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.32 $440.30M -$0.58 N/A Crescent Biopharma $10.84M 46.63 -$153.94M -$10.91 N/A

Does the media refer more to NVAX or CBIO?

In the previous week, Novavax had 3 more articles in the media than Crescent Biopharma. MarketBeat recorded 7 mentions for Novavax and 4 mentions for Crescent Biopharma. Novavax's average media sentiment score of 0.36 beat Crescent Biopharma's score of 0.33 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Crescent Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ZBIO or CBIO more profitable?

Zenas BioPharma's return on equity of -99.99% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Zenas BioPharma N/A -99.99% -58.06% Crescent Biopharma N/A -103.44% -88.19%

Does the media refer more to ZBIO or CBIO?

In the previous week, Crescent Biopharma had 1 more articles in the media than Zenas BioPharma. MarketBeat recorded 4 mentions for Crescent Biopharma and 3 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.63 beat Crescent Biopharma's score of 0.33 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crescent Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to OPK or CBIO?

In the previous week, OPKO Health had 2 more articles in the media than Crescent Biopharma. MarketBeat recorded 6 mentions for OPKO Health and 4 mentions for Crescent Biopharma. OPKO Health's average media sentiment score of 1.52 beat Crescent Biopharma's score of 0.33 indicating that OPKO Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Crescent Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MNKD or CBIO?

In the previous week, MannKind had 6 more articles in the media than Crescent Biopharma. MarketBeat recorded 10 mentions for MannKind and 4 mentions for Crescent Biopharma. MannKind's average media sentiment score of 0.74 beat Crescent Biopharma's score of 0.33 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crescent Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Crescent Biopharma (CBIO) Competitors

$18.34 +0.77 (+4.38%)

Closing price 04:00 PM Eastern

Extended Trading

$18.88 +0.54 (+2.96%)

As of 05:31 PM Eastern

Compare

CBIO vs. INVA, NVAX, ZBIO, OPK, and MNKD

Should you buy Crescent Biopharma stock or one of its competitors? MarketBeat compares Crescent Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Crescent Biopharma include Innoviva (INVA), Novavax (NVAX), Zenas BioPharma (ZBIO), OPKO Health (OPK), and MannKind (MNKD). These companies are all part of the "biotechnology" industry.

How does Crescent Biopharma compare to Innoviva?

Crescent Biopharma (NASDAQ:CBIO) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Crescent Biopharma has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 4.0% of Crescent Biopharma shares are held by company insiders. Comparatively, 2.0% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Innoviva has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	46.63	-$153.94M	-$10.91	N/A
Innoviva	$411.33M	4.03	$271.17M	$6.01	3.73

In the previous week, Crescent Biopharma and Crescent Biopharma both had 4 articles in the media. Innoviva's average media sentiment score of 0.47 beat Crescent Biopharma's score of 0.33 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innoviva	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Innoviva has a net margin of 119.89% compared to Crescent Biopharma's net margin of 0.00%. Innoviva's return on equity of 33.33% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
Innoviva	119.89%	33.33%	22.67%

Crescent Biopharma presently has a consensus target price of $28.00, suggesting a potential upside of 52.67%. Innoviva has a consensus target price of $36.20, suggesting a potential upside of 61.32%. Given Innoviva's higher probable upside, analysts plainly believe Innoviva is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Innoviva beats Crescent Biopharma on 10 of the 15 factors compared between the two stocks.

How does Crescent Biopharma compare to Novavax?

Novavax (NASDAQ:NVAX) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Novavax has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

Novavax currently has a consensus price target of $12.13, suggesting a potential upside of 34.27%. Crescent Biopharma has a consensus price target of $28.00, suggesting a potential upside of 52.67%. Given Crescent Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Crescent Biopharma is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

Crescent Biopharma has a net margin of 0.00% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Crescent Biopharma	N/A	-103.44%	-88.19%

Novavax has higher revenue and earnings than Crescent Biopharma. Novavax is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.32	$440.30M	-$0.58	N/A
Crescent Biopharma	$10.84M	46.63	-$153.94M	-$10.91	N/A

53.0% of Novavax shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Comparatively, 4.0% of Crescent Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Novavax had 3 more articles in the media than Crescent Biopharma. MarketBeat recorded 7 mentions for Novavax and 4 mentions for Crescent Biopharma. Novavax's average media sentiment score of 0.36 beat Crescent Biopharma's score of 0.33 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crescent Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Novavax and Crescent Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Crescent Biopharma compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Zenas BioPharma has a beta of -0.71, meaning that its stock price is 171% less volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Crescent Biopharma has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	112.12	-$377.74M	-$8.47	N/A
Crescent Biopharma	$10.84M	46.63	-$153.94M	-$10.91	N/A

Zenas BioPharma presently has a consensus target price of $44.29, indicating a potential upside of 149.36%. Crescent Biopharma has a consensus target price of $28.00, indicating a potential upside of 52.67%. Given Zenas BioPharma's higher possible upside, research analysts plainly believe Zenas BioPharma is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

In the previous week, Crescent Biopharma had 1 more articles in the media than Zenas BioPharma. MarketBeat recorded 4 mentions for Crescent Biopharma and 3 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.63 beat Crescent Biopharma's score of 0.33 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crescent Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.2% of Crescent Biopharma shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 4.0% of Crescent Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zenas BioPharma's return on equity of -99.99% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Crescent Biopharma	N/A	-103.44%	-88.19%

Summary

Zenas BioPharma and Crescent Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Crescent Biopharma compare to OPKO Health?

OPKO Health (NASDAQ:OPK) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Crescent Biopharma has a net margin of 0.00% compared to OPKO Health's net margin of -36.63%. OPKO Health's return on equity of -16.78% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Crescent Biopharma	N/A	-103.44%	-88.19%

OPKO Health presently has a consensus price target of $1.55, indicating a potential upside of 6.90%. Crescent Biopharma has a consensus price target of $28.00, indicating a potential upside of 52.67%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Crescent Biopharma is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.17
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 49.7% of OPKO Health shares are owned by company insiders. Comparatively, 4.0% of Crescent Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

OPKO Health has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Crescent Biopharma has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$606.90M	1.80	-$225.68M	-$0.27	N/A
Crescent Biopharma	$10.84M	46.63	-$153.94M	-$10.91	N/A

In the previous week, OPKO Health had 2 more articles in the media than Crescent Biopharma. MarketBeat recorded 6 mentions for OPKO Health and 4 mentions for Crescent Biopharma. OPKO Health's average media sentiment score of 1.52 beat Crescent Biopharma's score of 0.33 indicating that OPKO Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Crescent Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Crescent Biopharma beats OPKO Health on 9 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to MannKind?

MannKind (NASDAQ:MNKD) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

MannKind has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

In the previous week, MannKind had 6 more articles in the media than Crescent Biopharma. MarketBeat recorded 10 mentions for MannKind and 4 mentions for Crescent Biopharma. MannKind's average media sentiment score of 0.74 beat Crescent Biopharma's score of 0.33 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crescent Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

MannKind currently has a consensus price target of $8.97, indicating a potential upside of 139.17%. Crescent Biopharma has a consensus price target of $28.00, indicating a potential upside of 52.67%. Given MannKind's higher possible upside, research analysts plainly believe MannKind is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11

Crescent Biopharma has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Crescent Biopharma	N/A	-103.44%	-88.19%

49.6% of MannKind shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 2.6% of MannKind shares are owned by insiders. Comparatively, 4.0% of Crescent Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

MannKind has higher revenue and earnings than Crescent Biopharma. MannKind is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.32	$5.86M	-$0.07	N/A
Crescent Biopharma	$10.84M	46.63	-$153.94M	-$10.91	N/A

Summary

MannKind beats Crescent Biopharma on 9 of the 17 factors compared between the two stocks.

Get Crescent Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBIO vs. The Competition

Export

Metric	Crescent Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$484.17M	$2.95B	$6.47B	$11.73B
Dividend Yield	N/A	1.78%	2.67%	5.56%
P/E Ratio	-1.68	18.14	24.43	24.35
Price / Sales	46.63	294.55	503.66	108.33
Price / Cash	N/A	56.09	43.20	54.62
Price / Book	1.28	4.00	10.50	6.82
Net Income	-$153.94M	$75.85M	$3.56B	$337.41M
7 Day Performance	-0.53%	-1.99%	-2.02%	-0.96%
1 Month Performance	-0.97%	-3.48%	0.66%	1.68%
1 Year Performance	N/A	18.26%	21.85%	26.88%

Crescent Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBIO Crescent Biopharma	1.6739 of 5 stars	$18.34 +4.4%	$28.00 +52.7%	N/A	$484.17M	$10.84M	N/A	50
INVA Innoviva	3.9801 of 5 stars	$22.54 +0.9%	$36.20 +60.6%	+6.8%	$1.65B	$411.33M	3.75	100
NVAX Novavax	1.7864 of 5 stars	$8.67 +0.6%	$12.13 +39.9%	+18.9%	$1.42B	$1.12B	N/A	1,990
ZBIO Zenas BioPharma	3.4751 of 5 stars	$18.42 +4.6%	$44.29 +140.4%	+50.0%	$1.11B	$10M	N/A	N/A
OPK OPKO Health	1.9937 of 5 stars	$1.44 +0.7%	$1.55 +7.6%	+4.3%	$1.08B	$606.90M	N/A	1,373	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBIO) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crescent Biopharma (CBIO) Competitors

CBIO vs. INVA, NVAX, ZBIO, OPK, and MNKD

How does Crescent Biopharma compare to Innoviva?

Summary

How does Crescent Biopharma compare to Novavax?

Summary

How does Crescent Biopharma compare to Zenas BioPharma?

Summary

How does Crescent Biopharma compare to OPKO Health?

Summary

How does Crescent Biopharma compare to MannKind?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Crescent Biopharma (CBIO) Competitors

CBIO vs. INVA, NVAX, ZBIO, OPK, and MNKD

How does Crescent Biopharma compare to Innoviva?

Which has more risk & volatility, CBIO or INVA?

Do institutionals and insiders believe in CBIO or INVA?

Which has better earnings & valuation, CBIO or INVA?

Does the media favor CBIO or INVA?

Is CBIO or INVA more profitable?

Do analysts rate CBIO or INVA?

Summary

How does Crescent Biopharma compare to Novavax?

Which has more volatility and risk, NVAX or CBIO?

Do analysts prefer NVAX or CBIO?

Is NVAX or CBIO more profitable?

Which has preferable earnings & valuation, NVAX or CBIO?

Do institutionals & insiders believe in NVAX or CBIO?

Does the media refer more to NVAX or CBIO?

Summary

How does Crescent Biopharma compare to Zenas BioPharma?

Which has more risk & volatility, ZBIO or CBIO?

Which has stronger valuation & earnings, ZBIO or CBIO?

Do analysts prefer ZBIO or CBIO?

Does the media refer more to ZBIO or CBIO?

Do insiders & institutionals believe in ZBIO or CBIO?

Is ZBIO or CBIO more profitable?

Summary

How does Crescent Biopharma compare to OPKO Health?

Is OPK or CBIO more profitable?

Do analysts prefer OPK or CBIO?

Do insiders and institutionals believe in OPK or CBIO?

Which has more volatility & risk, OPK or CBIO?

Which has better earnings and valuation, OPK or CBIO?

Does the media refer more to OPK or CBIO?

Summary

How does Crescent Biopharma compare to MannKind?

Which has more risk & volatility, MNKD or CBIO?

Does the media refer more to MNKD or CBIO?

Do analysts recommend MNKD or CBIO?

Is MNKD or CBIO more profitable?

Do institutionals & insiders have more ownership in MNKD or CBIO?

Which has better earnings and valuation, MNKD or CBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools